Vivek Ramaswamy, an Indian-origin CEO, is making history by running for the US presidency in 2024. Ramaswamy, who is the founder and CEO of Roivant Sciences, a biopharmaceutical company, is the first Indian-origin person to run for the US presidency.
Ramaswamy, who was born in India and moved to the US at the age of four, is a graduate of Harvard Law School and Harvard Business School. He has worked in the private sector for over a decade, and is now the CEO of Roivant Sciences, a biopharmaceutical company that focuses on developing treatments for rare diseases.
Ramaswamy has said that he is running for president to bring a new perspective to the White House. He believes that the US needs to focus on creating jobs, improving education, and tackling climate change. He also wants to focus on improving healthcare and making sure that everyone has access to quality healthcare.
Ramaswamy has also said that he wants to bring a new approach to foreign policy, and that he wants to focus on building relationships with other countries. He believes that the US should be a leader in global affairs, and that it should be a force for good in the world.
Ramaswamy has already started to make a name for himself in the political world. He has been endorsed by several prominent figures, including former US President Barack Obama. He has also been endorsed by several prominent Indian-Americans, including former US Ambassador to India, Richard Verma.
Ramaswamy is a long shot for the 2024 US presidential election, but his candidacy is a sign of the changing times. He is the first Indian-origin person to run for the US presidency, and his candidacy is a sign that the US is becoming more diverse and inclusive. It is also a sign that the US is becoming more open to new ideas and perspectives.
Only time will tell if Ramaswamy will be successful in his bid for the US presidency, but his candidacy is a sign of the changing times. It is a sign that the US is becoming more diverse and inclusive, and that it is open to new ideas and perspectives.